



# Marksans Pharma Ltd.

June 19, 2025

**BSE Limited**

Corporate Relation Department  
Phiroze Jeejeebhoi Towers,  
Dalal Street,  
Mumbai - 400001.  
**Scrip Code: 524404**

**National Stock Exchange of India Limited**

Listing Department  
Exchange Plaza, C-1, Block-G,  
Bandra-Kurla Complex,  
Bandra (East), Mumbai - 400051.  
**Symbol: MARKSANS**

**Sub: Press Release**

**Marksans Pharma Limited's wholly owned subsidiary in the UK, Relonchem Limited receives Marketing Authorization for the product Oxybutynin hydrochloride 2.5mg/5ml Oral Solution.**

Marksans Pharma Limited (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) hereby announces that its wholly owned subsidiary Relonchem Limited has received Marketing Authorization for the product Oxybutynin hydrochloride 2.5mg/5ml Oral Solution from UK Medicines & Healthcare Products Regulatory Agency.

**For Marksans Pharma Limited**

Harshavardhan Panigrahi  
**Company Secretary**

**About Marksans Pharma Ltd**

Marksans Pharma Limited ([www.marksanspharma.com](http://www.marksanspharma.com)) headquartered at Mumbai, India is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities located in India, USA and UK are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Anti-diabetic, Pain Management, Gastroenterological and Anti-allergies. The company is marketing these products globally.

**Marksans Pharma Ltd.**

11<sup>th</sup> Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara,  
Andheri (W), Mumbai - 400 053 Tel.: +91 22 4001 2000 E-mail: [info@marksanspharma.com](mailto:info@marksanspharma.com)  
[www.marksanspharma.com](http://www.marksanspharma.com)